- Report
- August 2025
- 196 Pages
Global
From €3419EUR$3,939USD£2,964GBP
- Report
- August 2025
- 196 Pages
Global
From €3419EUR$3,939USD£2,964GBP
- Report
- August 2025
- 190 Pages
Global
From €3419EUR$3,939USD£2,964GBP
- Report
- August 2025
Global
From €4297EUR$4,950USD£3,725GBP
- Report
- December 2025
- 196 Pages
Global
From €4253EUR$4,900USD£3,688GBP
- Report
- September 2025
- 250 Pages
Global
From €3897EUR$4,490USD£3,379GBP
- Report
- January 2026
- 287 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 281 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 224 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 377 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 377 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 476 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 419 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 482 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 577 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 483 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 297 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 211 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 291 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 196 Pages
Global
From €5078EUR$5,850USD£4,402GBP

Bispecific antibodies are a type of biotechnology that are used to target two different antigens simultaneously. They are engineered to bind to two different epitopes on the same or different antigens, allowing them to act as a bridge between two different cells or molecules. Bispecific antibodies have been used in a variety of therapeutic applications, including cancer immunotherapy, autoimmune diseases, and infectious diseases.
Bispecific antibodies have the potential to improve the efficacy of existing treatments and to develop new treatments for diseases that have not yet been addressed. They can also be used to target multiple antigens at once, allowing for more efficient and effective treatments.
The bispecific antibodies market is expected to grow significantly in the coming years due to the increasing demand for targeted therapies and the development of new technologies. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more